Novartis backs Epsilogen's bid to turn 'Cinderella antibody' into new class of cancer drug

Novartis has thrown its weight behind a “Cinderella antibody,” leading a 30.8 million pound sterling ($40.9 million) series B round that positions Epsilogen to try to create “a brand new category of pharmaceutical within within cancer.”